

Thierry Guillaume

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/230803/publications.pdf>

Version: 2024-02-01

90
papers

994
citations

516561

16
h-index

501076

28
g-index

95
all docs

95
docs citations

95
times ranked

1562
citing authors

#	ARTICLE	IF	CITATIONS
1	Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. <i>International Journal of Cancer</i> , 2004, 110, 741-750.	2.3	83
2	Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 5192-5197.	0.8	79
3	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 1815-1826.	1.3	75
4	Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2021, 4, e2126344.	2.8	55
5	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Oncotarget</i> , 2018, 9, 11451-11464.	0.8	46
6	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 184-191.	1.7	43
7	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. <i>Lancet Haematology</i> , the, 2015, 2, e108-e117.	2.2	36
8	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkinâ€™s lymphoma undergoing allogeneic haematopoietic cell transplantationâ€”a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	1.3	34
9	Allogeneic hematopoietic stem cell transplantation for <sc>T</sc>â€™prolymphocytic leukemia: a report from the <sc>F</sc>rench society for stem cell transplantation (<sc>SFGM</sc>â€™<sc>TC</sc>). <i>European Journal of Haematology</i> , 2015, 94, 265-269.	1.1	33
10	Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cellâ€™Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. <i>Journal of Immunology</i> , 2019, 202, 2141-2152.	0.4	32
11	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	1.7	26
12	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <i>Haematologica</i> , 2014, 99, 1486-1491.	1.7	25
13	Safety and antibody response after one and/or two doses of BNT162b2 Antiâ€™SARSâ€™CoVâ€™2 mRNA vaccine in patients treated by CAR T cells therapy. <i>British Journal of Haematology</i> , 2022, 196, 360-362.	1.2	24
14	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 448.	2.1	24
15	Interest of a third dose of BNT162b2 antiâ€™SARSâ€™CoVâ€™2 messenger RNA vaccine after allotransplant. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	21
16	Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries. <i>Cancer Research</i> , 2002, 62, 4985-91.	0.4	19
17	Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 839.e1-839.e6.	0.6	18
18	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i> , 2018, 9, 33528-33535.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Complete Donor T Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced-Intensity Conditioning Regimen Allogeneic Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 180-184.	2.0	16
20	A novel complete blood countâ€based score to screen for myelodysplastic syndrome in cytopenic patients. <i>British Journal of Haematology</i> , 2018, 183, 736-746.	1.2	15
21	Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. <i>Cancers</i> , 2020, 12, 1927.	1.7	15
22	In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1337-1352.	2.0	15
23	Clofarabine versus fludarabineâ€based reducedâ€intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. <i>Cancer Medicine</i> , 2016, 5, 3068-3076.	1.3	13
24	Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. <i>Annals of Hematology</i> , 2020, 99, 1855-1862.	0.8	13
25	Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults. <i>Blood</i> , 2014, 124, 2479-2479.	0.6	13
26	A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3511-3514.	1.4	12
27	Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective realâ€life study. <i>British Journal of Haematology</i> , 2021, 194, 336-343.	1.2	12
28	Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1162-1162.	0.6	11
29	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. <i>Haematologica</i> , 2021, 106, 701-707.	1.7	10
30	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 279.e1-279.e4.	0.6	10
31	Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. <i>Journal of Immunology</i> , 2020, 205, 1441-1448.	0.4	9
32	Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 395-399.	1.3	8
33	Effectiveness of a third dose of BNT162b2 antiâ€SARSâ€CoVâ€2 mRNA vaccine over a 6â€month followâ€up period in allogeneic hematopoietic stem cells recipients. <i>Hematological Oncology</i> , 2022, 40, 1097-1099.	0.8	8
34	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2020, 99, 1341-1350.	0.8	7
35	MIDAM Regimen (Mylotarg + Intermediate Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.. <i>Blood</i> , 2006, 108, 1957-1957.	0.6	7
36	Phase II Prospective Multicentre Study Testing The Efficacy and Safety Of a Clofarabine (Clo), I.v. Busulfan (Bu) and Antithymocyte Globulins (ATG)-Based Reduced-Intensity Conditioning Regimen (RIC) Before Allogeneic Stem Cell Transplantation (allo-SCT) For High-Risk Myelodysplastic Syndrome Or Acute Leukemia: The Cloric Trial. <i>Blood</i> , 2013, 122, 413-413.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Anti-CD34+ fabs generated against hematopoietic stem cells in HIV-derived combinatorial immunoglobulin library suggest antigen-selected autoantibodies Research supported by Grant AG00537 from the National Institutes of Health, Bethesda, and by the nato International Scientific Exchange Programme, Brussels.. <i>Molecular Immunology</i> , 1998, 35, 955-964.	1.0	6
38	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	1.7	6
39	Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1044-1047.	1.3	6
40	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
41	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>Oncotarget</i> , 2018, 9, 36603-36612.	0.8	6
42	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?. <i>European Journal of Haematology</i> , 2017, 99, 60-69.	1.1	5
43	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. <i>Blood</i> , 2016, 128, 5268-5268.	0.6	5
44	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	0.7	5
45	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021, 60, 466-474.	0.8	4
46	Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. <i>Cancer Medicine</i> , 2021, 10, 7194-7202.	1.3	4
47	Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study. <i>Blood</i> , 2016, 128, 4018-4018.	0.6	4
48	Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant. <i>EJHaem</i> , 2022, , .	0.4	4
49	Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. <i>Experimental Hematology</i> , 2019, 70, 97-108.	0.2	3
50	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. <i>Scientific Reports</i> , 2020, 10, 15399.	1.6	3
51	Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. <i>British Journal of Haematology</i> , 2020, 190, 461-464.	1.2	3
52	Deciphering the biology of KIR2DL3+ T lymphocytes that are associated to relapse in haploidentical HSCT. <i>Scientific Reports</i> , 2021, 11, 15782.	1.6	3
53	Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 4555-4555.	0.6	3
54	A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial). <i>Blood</i> , 2016, 128, 2821-2821.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Eltrombopag induces major non-toxic hypersiderraemia. British Journal of Haematology, 2019, 186, 365-366.	1.2	2
56	Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1465-1471.	2.0	2
57	Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure. Blood, 2014, 124, 1228-1228.	0.6	2
58	Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies. Bone Marrow Transplantation, 2022, 57, 1435-1441.	1.3	2
59	FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine, 2019, 120, 85-87.	1.4	1
60	Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 514-514.	0.6	1
61	No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients. Blood, 2015, 126, 2520-2520.	0.6	1
62	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3911-3911.	0.6	1
63	Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 861.e1-861.e7.	0.6	0
64	Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimen (RIC) for Adult Patients with AML: Same Results in Secondary and De Novo AML.. Blood, 2006, 108, 3015-3015.	0.6	0
65	Outcomes After a Sequential Clofarabine/Arac-C Chemotherapy Followed By Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) In Pediatrics Patients With JMML Or Primary/Relapsed Refractory AML: A Pilot Study. Blood, 2013, 122, 5460-5460.	0.6	0
66	BCR-ABL1 Molecular Remission After 90y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22+ Ph+ B-ALL: A Potential New Treatment Paradigm. Blood, 2013, 122, 3910-3910.	0.6	0
67	Long-Lasting HHV-6 Reactivation and Immune Recovery In Adult Long-Survivors After Umbilical Cord Blood (UCB) Allo-SCT: A Comparison With PBSC As Stem-Cell Source. Blood, 2013, 122, 2065-2065.	0.6	0
68	HLA-A, -B, -C and "DRB1 High Resolution Matching Can Improve Patient' Outcome After Double Umbilical Allogeneic Stem Cell Transplantation (allo-SCT). Blood, 2013, 122, 414-414.	0.6	0
69	Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. Blood, 2014, 124, 5923-5923.	0.6	0
70	Chemoimmunotherapy Combining Vincristine, Dexamethasone and Epratuzumab (hLL2) As Salvage Regimen for Older Relapsed/Refractory, CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Patients: Results of the French Non-Intensive Phase 2 Prospective Cheprall Study. Blood, 2014, 124, 3710-3710.	0.6	0
71	Post-Transplant Cyclophosphamide (PTCY) Vs Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) in Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Immune Reconstitution. Blood, 2015, 126, 1955-1955.	0.6	0
72	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. Blood, 2015, 126, 3218-3218.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Targeting Cell-Bound MUC1 on Myelomonocytic and Monocytic Leukemias and Leukemic Stem Cells: Therapeutic Implications. <i>Blood</i> , 2015, 126, 2899-2899.	0.6	0
74	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. <i>Blood</i> , 2015, 126, 4339-4339.	0.6	0
75	Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier. <i>Blood</i> , 2015, 126, 5519-5519.	0.6	0
76	CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC. <i>Blood</i> , 2015, 126, 1908-1908.	0.6	0
77	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. <i>Blood</i> , 2015, 126, 1947-1947.	0.6	0
78	Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases. <i>Blood</i> , 2015, 126, 3122-3122.	0.6	0
79	Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Tj ETQq1 1 @784314 rgBT /Ov	0.6	0
80	Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells. <i>Blood</i> , 2016, 128, 5866-5866.	0.6	0
81	In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR). <i>Blood</i> , 2016, 128, 5193-5193.	0.6	0
82	Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy). <i>Blood</i> , 2016, 128, 4594-4594.	0.6	0
83	Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3319-3319.	0.6	0
84	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen. <i>Blood</i> , 2019, 134, 1985-1985.	0.6	0
85	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. <i>Blood</i> , 2019, 134, 5771-5771.	0.6	0
86	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2021, 138, 3465-3465.	0.6	0
87	Comparable Outcomes Among Adult Patients Allotransplanted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. <i>Blood</i> , 2021, 138, 4914-4914.	0.6	0
88	Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine. <i>Blood</i> , 2021, 138, 2895-2895.	0.6	0
89	Gut Microbiota-Induced Regulatory T Cells in Patients with Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Towards Deciphering a Role for These Tregs in aGVHD. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
90	Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases. <i>Blood</i> , 2020, 136, 37-38.	0.6	0